FDA’s Approach to Decentralized Clinical Trials in the United States

Introduction

Decentralized clinical trials (DCTs) have emerged as a pivotal innovation in U.S. clinical research, particularly after the COVID-19 pandemic. The Food and Drug Administration (FDA) has recognized DCTs as a way to improve patient access, diversity, and trial efficiency while maintaining data integrity and participant safety. DCTs incorporate remote assessments, telemedicine, eConsent, wearable devices, and direct-to-patient drug delivery. In 2023, FDA issued draft guidance clarifying its regulatory expectations for DCTs, signaling a long-term commitment to these models. This article explores FDA’s perspective on DCTs, operational strategies, compliance considerations, and case studies from U.S. clinical research.

Background / Regulatory Framework

FDA Draft Guidance 2023

The May 2023 FDA draft guidance on decentralized clinical trials outlines regulatory expectations for remote assessments, informed consent, digital tools, and data security. While DCTs are not mandated, FDA encourages their use when appropriate to enhance diversity, reduce burden, and expand trial reach. The guidance builds on earlier COVID-19 flexibilities, formalizing long-term standards for decentralized approaches.

ICH and Global Context

Although ICH guidelines do not explicitly reference DCTs, FDA aligns DCT principles with ICH E6(R2) GCP and ICH E8 (R1) on trial design. Global regulators such as EMA and MHRA have also issued decentralized trial guidance, making harmonization an important consideration for multinational sponsors.

Case Example—Hybrid Diabetes Trial

A U.S. diabetes trial implemented telemedicine, eConsent, and home health visits. FDA inspectors later reviewed the hybrid model and confirmed compliance, citing robust data validation and HIPAA adherence.

Core Clinical Trial Insights

1) Key Features of DCTs

DCTs use digital health technologies and remote models to decentralize trial activities. Features include eConsent, remote assessments, wearable data, direct-to-patient IP shipping, home health visits, and telemedicine consultations.

2) Regulatory Oversight

FDA expects sponsors to validate digital systems, ensure audit trails, and maintain Part 11 and HIPAA compliance. Sponsors must document roles and responsibilities for investigators, CROs, and vendors in managing decentralized elements.

3) Informed Consent and Ethics

FDA accepts eConsent in decentralized models but requires that it be validated, accessible, and accompanied by opportunities for live discussions with investigators. IRBs review eConsent content and procedures for compliance.

4) Investigator Oversight

Despite decentralization, investigators remain responsible for participant safety and data integrity. FDA expects investigators to maintain oversight of all remote activities, including telemedicine assessments and home health providers.

5) Patient Recruitment and Diversity

DCTs can improve diversity by reducing geographic and logistical barriers. FDA encourages sponsors to use decentralized strategies to enroll underrepresented populations in line with diversity guidance issued in 2022.

6) Digital Tools and Validation

Wearables, apps, and ePRO systems must be validated for accuracy, usability, and cybersecurity. FDA requires documented validation and evidence of reliability in regulatory submissions.

7) Data Integrity

FDA applies ALCOA+ principles to decentralized data. Sponsors must ensure contemporaneous entry, traceability, and auditability. Cybersecurity and HIPAA protections are mandatory.

8) CRO and Vendor Management

CROs and vendors play key roles in DCTs, managing digital tools, logistics, and remote monitoring. Sponsors must qualify and oversee vendors to ensure regulatory compliance.

9) Inspection Readiness

FDA inspections of DCTs review eTMFs, audit trails, telemedicine logs, and vendor oversight. Sponsors must ensure all decentralized activities are inspection-ready throughout the trial.

10) Operational Challenges

Challenges include internet access disparities, patient training on digital tools, ensuring protocol adherence remotely, and maintaining consistent global regulatory alignment. Sponsors must develop mitigation strategies.

Best Practices & Preventive Measures

Sponsors should: (1) validate all digital tools; (2) prepare clear SOPs for decentralized activities; (3) train staff and patients; (4) ensure HIPAA and Part 11 compliance; (5) maintain robust vendor oversight; (6) use hybrid models to balance efficiency and oversight; (7) engage FDA early on novel designs; (8) implement risk-based monitoring; and (9) maintain inspection-ready documentation at all times.

Scientific & Regulatory Evidence

References include FDA’s May 2023 draft guidance on DCTs, FDA’s 2020 COVID-19 guidance, 21 CFR Part 11, HIPAA, ICH E6(R2) GCP, and ICH E8 (R1). Together, these documents establish the scientific and regulatory foundation for decentralized clinical trials in the U.S.

Special Considerations

Pediatric and rare disease DCTs present unique challenges, including guardian consent, digital literacy, and ethical considerations for vulnerable populations. FDA expects sponsors to demonstrate safeguards and equitable access in these trials.

When Sponsors Should Seek Regulatory Advice

Sponsors should seek FDA input during pre-IND or pre-submission meetings when implementing novel decentralized approaches, digital endpoints, or home health interventions. Early engagement mitigates regulatory risks and ensures acceptability.

Case Studies

Case Study 1: Remote Oncology Trial

A U.S. oncology trial integrated telehealth, remote labs, and wearable monitoring. FDA accepted the data and commended the sponsor’s robust oversight, supporting broader adoption of hybrid oncology models.

Case Study 2: Rural Recruitment Expansion

A cardiovascular trial used decentralized strategies to recruit rural patients through home visits and eConsent. Enrollment increased by 20%, demonstrating DCTs’ role in improving access.

Case Study 3: Digital Endpoint Validation

A neurology trial used wearable-based endpoints for activity monitoring. FDA accepted the digital measures after validation, setting precedent for future digital biomarker submissions.

FAQs

1) What is a decentralized clinical trial (DCT)?

A trial that uses digital and remote methods to conduct activities outside traditional research sites, such as telehealth, eConsent, and wearables.

2) Does FDA accept DCT models?

Yes, FDA encourages DCTs when appropriate, provided systems are validated, HIPAA compliant, and Part 11 compliant.

3) What are FDA’s main concerns with DCTs?

Data integrity, investigator oversight, patient safety, and system validation.

4) Can eConsent be used in DCTs?

Yes, eConsent is accepted if validated and reviewed by IRBs, with opportunities for investigator interaction.

5) How do DCTs affect recruitment?

DCTs expand access and diversity by reducing travel burden and enabling rural participation.

6) What systems must be validated?

All electronic systems used in DCTs, including ePRO, wearables, EHR integration, and remote monitoring tools.

7) How does FDA inspect DCTs?

Through BIMO inspections reviewing audit trails, eTMFs, vendor oversight, and data validation.

8) Are hybrid models common in the U.S.?

Yes, most sponsors use hybrid models that blend site visits with decentralized elements to balance oversight and convenience.

Conclusion & Call-to-Action

Decentralized clinical trials are reshaping U.S. research by improving access, diversity, and efficiency. FDA’s evolving guidance provides a clear framework for compliance, but sponsors must ensure validation, oversight, and patient protection. By adopting best practices and engaging FDA early, sponsors can leverage DCTs to accelerate development and build resilient clinical trial models for the future.